View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2021updated 11 Jul 2022 2:52pm

Newron commences trial of evenamide in schizophrenia patients

The trial is designed to assess the efficacy, tolerability and safety of the new chemical entity in nearly 200 subjects.

Newron Pharmaceuticals has commenced a pivotal four-week clinical trial, Study 008A, assessing its orally available compound, evenamide, as an add-on treatment for schizophrenia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A new chemical entity, evenamide selectively acts on voltage-gated sodium channels to treat the condition.

The drug’s mechanism of action involves glutamate modulation and voltage-gated sodium channel hindering. This glutamatergic inhibition provides a novel treatment option to patients who have no benefit from existing antipsychotic therapies.

The randomised, double-blind, placebo-controlled, global Study 008A will analyse the efficacy, tolerability and safety of the 30mg twice-daily therapeutic dose of evenamide in chronic schizophrenia patients.

It will include subjects who are already receiving a second-generation antipsychotic.

The impact of the drug on the electroencephalogram (EEG) will also be evaluated.

The company intends to enrol a minimum of 200 subjects at trial sites across Europe, Asia and Latin America.

The study is part of the company’s Phase III evenamide clinical trial programme in schizophrenia patients who experience psychosis worsening on receiving therapeutic doses of atypical antipsychotics and those unresponsive to treatment.

Newron anticipates data from the latest study in the fourth quarter of next year.

Newron Pharmaceuticals CMO Ravi Anand said: “If successful, Newron believes the study would qualify as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.

“Evenamide would currently be the first add-on therapy approved for the treatment of patients with positive symptoms of schizophrenia, and its unique glutamatergic inhibition mechanism of action offers a truly innovative therapeutic option to those patients who are not benefitting from their current antipsychotics.”

Evenamide showed efficacy in substantially improving psychosis symptoms versus placebo when given with two most commonly used atypical antipsychotics in a Phase IIa trial involving chronic schizophrenia patients.

Furthermore, the drug was demonstrated to be safe in trials involving more than 300 healthy subjects and patients at doses of up to 60mg.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena